Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Years matter.
Patients matter more.

CardioMEMs HF System 10 year anniversary

CardioMEMS HF System

You can count on the CardioMEMS™ HF System - The only remote hemodynamic monitor with a decade of expert experience and trusted support.

Watch Alicia's story to hear how her life has been transformed in countless ways.

This testimonial relays an account of an individual's response to treatment. This patient's account is genuine, typical, and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to treatment discussed can and do vary and are specific to the individual patient. 

10 years of the CardioMEMS HF System

Lowers pulmonary artery (PA) pressure1

Lowers pulmonary artery pressure

Reduces the risk of mortality at 2 years in HFrEF patients2

Reduced risk of mortality

Reduces heart failure hospitalization (HFH) at 2 years3

Reduces heart failure hospitalizations

Reduces 30-day HFH readmissions4

Reduces 30-day HFH readmissions

Significantly improves quality of life as early as 3 months post-implant5

Improves quality of life

Proven benefits regardless of ejection fraction1,6

Proven benefits

Device the size of a paperclip

Device the size of a paperclip

Presymptomatic data means more time to optimize GDMT

time to optimize GDMT

Suitable for right or left PA placement

Suitable for left or right placement

Unmatched experience that’s continuously growing:

  • 35k+ patients helped to date.7
  • 8k+ patients included in clinical and real-world studies.7
  • 20+ countries implanting since 2014.7
unmatched experience

Talk to a clinical specialist to learn more about recent clinical and real-world data.

Talk to a specialist
Talk to a Clinical Specialist
View Clinical Data

References

  1. Lindenfeld J, Zile MR, Desai AS, et al. Hemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. Lancet. 2021;398:991–1001.
  2. Lindenfeld J, on behalf of the GUIDE-HF, CHAMPION and LAPTOP-HF Investigators. Longer-term effects of hemodynamic monitoring on outcomes: a combined data analysis of patients with HFrEF in CHAMPION, GUIDE-HF and LAPTOP-HF. Presented at: Technology and Heart Failure Therapeutics (THT) Conference; March 21, 2023; Boston, MA
  3. Heywood TT et al. Sustained reduction in pulmonary artery pressures and hospitalizations during 2 years of ambulatory monitoring. J Card Fail. 2023;29(1):56–66.
  4. Adamson et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. Circ Heart Fail. 2016;115.002600.
  5. Brugts JJ et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. 2023;401:2113–2123.
  6. Shavelle D, Desai A, Abraham W, et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circ Heart Fail. Published online 2020. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006863.
  7. Abbott. Data on file.

MAT-2407600 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0